(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.21%) $11.02
(0.56%) $0.808
(-0.95%) $93.01
Live Chart Being Loaded With Signals
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes...
Stats | |
---|---|
Today's Volume | 198 647 |
Average Volume | 338 377 |
Market Cap | 81.72M |
EPS | $0 ( 2024-02-22 ) |
Next earnings date | ( $0 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -19.48 |
ATR14 | $0.00500 (2.57%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-04-06 | Pershing Edward | Buy | 47 190 | Series D-1 Convertible Preferred Stock |
2024-04-06 | Pershing Edward | Sell | 0 | 8% Unsecured Convertible Promissory Note |
2024-03-26 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-03-21 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 17 773 792 | Sell: 0 |
Provectus Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Provectus Financials
Annual | 2023 |
Revenue: | $557 710 |
Gross Profit: | $548 789 (98.40 %) |
EPS: | $-0.00740 |
Q4 | 2023 |
Revenue: | $121 110 |
Gross Profit: | $118 880 (98.16 %) |
EPS: | $-0.00160 |
Q3 | 2023 |
Revenue: | $69 733.00 |
Gross Profit: | $67 503.00 (96.80 %) |
EPS: | $-0.00180 |
Q2 | 2023 |
Revenue: | $161 842 |
Gross Profit: | $148 408 (91.70 %) |
EPS: | $-0.00200 |
Financial Reports:
No articles found.
Provectus
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators